RAVENQUEST COMPLETES FIRST CANNABIS SHIPMENT TO AUSTRALIA
NR19-25 - November 12, 2019 – Vancouver, British Columbia – RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest” - https://www.commodity-tv.com/play/ravenquest-biomed-investor-presentation-in-frankfurt-germany/ ), one of Canada’s most innovative cannabis companies, announces it has successfully completed its first shipment of medical cannabis to Australia. RavenQuest cannabis was shipped to Medcan Australia (“Medcan”), a federally licensed Australian medical cannabis provider.
“On November 8, 2019, Medcan took delivery of a nominal supply of cannabis which originated from RavenQuest’s Edmonton facility, grown using RavenQuest’s Orbital Garden cannabis grow technology. While the size of the shipment is nominal, what is important is that we were able to execute the shipment to our Australian partners without any serious delays or snags in the process. During this test shipment, the process went very smoothly which we believe will allow us to quickly go to the next level with Australia, shipping larger quantities to our partner, Medcan” stated George Robinson, CEO of RavenQuest.
“For those unfamiliar with the Australian market, it is a burgeoning cannabis marketplace with a regulatory framework that resembles Canada’s medical marijuana laws circa 2001-2010. Pricing in Australia is very favourable for producers, and we look forward to shipping more of our high-quality, Orbital Garden-grown cannabis to our Australian friends” Robinson continued.
Medcan CEO, Craig Cochran, commented, “After receiving our first RavenQuest cannabis shipment, we can confirm that RavenQuest’s cannabis quality meets our high product standards, which is a testament to their precision-controlled indoor cultivation methods. Even more importantly, it allows us to provide high-quality cannabis to our patients.”
Founded in 2016, Medcan has a singular vision to provide Australian patients with a high-quality, fair-priced cannabis product. With a vertically integrated model, Medcan is licenced under the Australian Office of Drug Control to cultivate, produce, manufacture, export and import high-quality medicinal cannabis products for both clinical trials and individual patient access throughout Australia.
For more information, please access RavenQuest’s investor presentation, fact sheet and videos here.
About RavenQuest BioMed Inc.
RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer of cannabis with facilities located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company also focuses on partnerships with Indigenous communities.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
Chief Executive Officer
For further information, please contact: Mathieu McDonald, Corporate Communication +1-877-282-1586
Swiss Resource Capital AG
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. Examples of such statements include statements with respect to future shipments of cannabis to Medcan in Australia. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.